Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Huons

Status and phase: Enrolling; Phase 3

Conditions: Primary Open Angle Glaucoma (POAG); Ocular Hypertension

Treatments: Drug: HUC3-637; Drug: HUC3-637-R

Study type: Interventional

Funder types: Industry

Identifiers

NCT07335211

HUC3-637

Details and patient eligibility

About

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Enrollment: 206 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults aged 19 years and older
• Participants diagnosed with POAG or OH
• Have fully explained and understood the study and have voluntarily given written informed consent.

Exclusion criteria

• Acute or chronic angle-closure glaucoma
• Congenital glaucoma, secondary glaucoma (open-angle glaucoma)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

206 participants in 2 patient groups

HUC3-637

Experimental group

Description:

Dorzolamide, Timolol

Treatment:

Drug: HUC3-637

HUC3-637-R

Active Comparator group

Description:

Dorzolamide, Timolol

Treatment:

Drug: HUC3-637-R